A citation-based method for searching scientific literature

Kenneth M Borow, John R Nelson, R Preston Mason. Atherosclerosis 2015
Times Cited: 102







List of co-cited articles
702 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura,[...]. Lancet 2007
58

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
43

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Christie M Ballantyne, Harold E Bays, John J Kastelein, Evan Stein, Jonathan L Isaacsohn, Rene A Braeckman, Paresh N Soni. Am J Cardiol 2012
224
38



Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.
Harold E Bays, Christie M Ballantyne, Rene A Braeckman, William G Stirtan, Paresh N Soni. Am J Cardiovasc Drugs 2013
91
27

A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins.
Tetsu Watanabe, Kaoru Ando, Hyuma Daidoji, Yoichiro Otaki, Shigeo Sugawara, Motoyuki Matsui, Eiichiro Ikeno, Osamu Hirono, Hiroshi Miyawaki, Yoshinori Yashiro,[...]. J Cardiol 2017
74
33

Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Louise Bowman, Marion Mafham, Karl Wallendszus, Will Stevens, Georgina Buck, Jill Barton, Kevin Murphy, Theingi Aung, Richard Haynes, Jolyon Cox,[...]. N Engl J Med 2018
307
22

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.
Theingi Aung, Jim Halsey, Daan Kromhout, Hertzel C Gerstein, Roberto Marchioli, Luigi Tavazzi, Johanna M Geleijnse, Bernhard Rauch, Andrew Ness, Pilar Galan,[...]. JAMA Cardiol 2018
353
21

Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma.
Ryo Nishio, Toshiro Shinke, Hiromasa Otake, Masayuki Nakagawa, Ryoji Nagoshi, Takumi Inoue, Amane Kozuki, Hirotoshi Hariki, Tsuyoshi Osue, Yu Taniguchi,[...]. Atherosclerosis 2014
73
27

Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.
Terry A Jacobson, Sara B Glickstein, Jonathan D Rowe, Paresh N Soni. J Clin Lipidol 2012
170
20


Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes.
R Preston Mason, Robert F Jacob, Sandeep Shrivastava, Samuel C R Sherratt, Amitabha Chattopadhyay. Biochim Biophys Acta 2016
72
27

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.
Abbie L Cawood, Ren Ding, Frances L Napper, Ruth H Young, Jennifer A Williams, Matthew J A Ward, Ola Gudmundsen, Runar Vige, Simon P K Payne, Shu Ye,[...]. Atherosclerosis 2010
146
19

Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
Deepak L Bhatt, Ph Gabriel Steg, Eliot A Brinton, Terry A Jacobson, Michael Miller, Jean-Claude Tardif, Steven B Ketchum, Ralph T Doyle, Sabina A Murphy, Paresh N Soni,[...]. Clin Cardiol 2017
106
19

Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.
JoAnn E Manson, Nancy R Cook, I-Min Lee, William Christen, Shari S Bassuk, Samia Mora, Heike Gibson, Christine M Albert, David Gordon, Trisha Copeland,[...]. N Engl J Med 2019
393
19

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
Jackie Bosch, Hertzel C Gerstein, Gilles R Dagenais, Rafael Díaz, Leanne Dyal, Hyejung Jung, Aldo P Maggiono, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
587
18

Effects of extended-release niacin with laropiprant in high-risk patients.
Martin J Landray, Richard Haynes, Jemma C Hopewell, Sarah Parish, Theingi Aung, Joseph Tomson, Karl Wallendszus, Martin Craig, Lixin Jiang, Rory Collins,[...]. N Engl J Med 2014
973
18

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
17

Relationships between plasma fatty acid composition and coronary artery disease.
Hiroshige Itakura, Mitsuhiro Yokoyama, Masunori Matsuzaki, Yasushi Saito, Hideki Origasa, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Toru Kita,[...]. J Atheroscler Thromb 2011
158
17


Effects of combination lipid therapy in type 2 diabetes mellitus.
Henry N Ginsberg, Marshall B Elam, Laura C Lovato, John R Crouse, Lawrence A Leiter, Peter Linz, William T Friedewald, John B Buse, Hertzel C Gerstein, Jeffrey Probstfield,[...]. N Engl J Med 2010
17

Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management.
Om P Ganda, Deepak L Bhatt, R Preston Mason, Michael Miller, William E Boden. J Am Coll Cardiol 2018
100
17

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
Michael Miller, Neil J Stone, Christie Ballantyne, Vera Bittner, Michael H Criqui, Henry N Ginsberg, Anne Carol Goldberg, William James Howard, Marc S Jacobson, Penny M Kris-Etherton,[...]. Circulation 2011
16

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
Stephen J Nicholls, A Michael Lincoff, Dianna Bash, Christie M Ballantyne, Philip J Barter, Michael H Davidson, John J P Kastelein, Wolfgang Koenig, Darren K McGuire, Dariush Mozaffarian,[...]. Clin Cardiol 2018
127
16

n-3 fatty acids and cardiovascular events after myocardial infarction.
Daan Kromhout, Erik J Giltay, Johanna M Geleijnse. N Engl J Med 2010
626
15

Residual macrovascular risk in 2013: what have we learned?
Jean-Charles Fruchart, Jean Davignon, Michel P Hermans, Khalid Al-Rubeaan, Pierre Amarenco, Gerd Assmann, Philip Barter, John Betteridge, Eric Bruckert, Ada Cuevas,[...]. Cardiovasc Diabetol 2014
120
15

Effects of the Addition of Eicosapentaenoic Acid to Strong Statin Therapy on Inflammatory Cytokines and Coronary Plaque Components Assessed by Integrated Backscatter Intravascular Ultrasound.
Toshiyuki Niki, Tetsuzo Wakatsuki, Koji Yamaguchi, Yoshio Taketani, Hiroyasu Oeduka, Kenya Kusunose, Takayuki Ise, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki,[...]. Circ J 2016
52
28

Potential benefits of eicosapentaenoic acid on atherosclerotic plaques.
J R Nelson, O Wani, H T May, M Budoff. Vascul Pharmacol 2017
43
34


Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. J Am Coll Cardiol 2019
136
15

Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
R Preston Mason, Peter Libby, Deepak L Bhatt. Arterioscler Thromb Vasc Biol 2020
105
15

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
John J P Kastelein, Kevin C Maki, Andrey Susekov, Marat Ezhov, Borge G Nordestgaard, Ben N Machielse, Douglas Kling, Michael H Davidson. J Clin Lipidol 2014
155
14

OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.
Bernhard Rauch, Rudolf Schiele, Steffen Schneider, Frank Diller, Norbert Victor, Helmut Gohlke, Martin Gottwik, Gerhard Steinbeck, Ulrike Del Castillo, Rudolf Sack,[...]. Circulation 2010
384
14



Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.
Christie M Ballantyne, Harold E Bays, Rene A Braeckman, Sephy Philip, William G Stirtan, Ralph T Doyle, Paresh N Soni, Rebecca A Juliano. J Clin Lipidol 2016
32
43

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
William E Boden, Jeffrey L Probstfield, Todd Anderson, Bernard R Chaitman, Patrice Desvignes-Nickens, Kent Koprowicz, Ruth McBride, Koon Teo, William Weintraub. N Engl J Med 2011
14

Remnant cholesterol as a causal risk factor for ischemic heart disease.
Anette Varbo, Marianne Benn, Anne Tybjærg-Hansen, Anders B Jørgensen, Ruth Frikke-Schmidt, Børge G Nordestgaard. J Am Coll Cardiol 2013
528
13

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
Luigi Tavazzi, Aldo P Maggioni, Roberto Marchioli, Simona Barlera, Maria Grazia Franzosi, Roberto Latini, Donata Lucci, Gian Luigi Nicolosi, Maurizio Porcu, Gianni Tognoni. Lancet 2008
882
13

Loss-of-function mutations in APOC3, triglycerides, and coronary disease.
Jacy Crosby, Gina M Peloso, Paul L Auer, David R Crosslin, Nathan O Stitziel, Leslie A Lange, Yingchang Lu, Zheng-zheng Tang, He Zhang, George Hindy,[...]. N Engl J Med 2014
677
13


Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Michael Miller, Christopher P Cannon, Sabina A Murphy, Jie Qin, Kausik K Ray, Eugene Braunwald. J Am Coll Cardiol 2008
402
13



Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.
Anders Berg Jørgensen, Ruth Frikke-Schmidt, Børge G Nordestgaard, Anne Tybjærg-Hansen. N Engl J Med 2014
569
12

Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia.
Nobuaki Tanaka, Tatsuro Ishida, Manabu Nagao, Takeshige Mori, Tomoko Monguchi, Maki Sasaki, Kenta Mori, Kensuke Kondo, Hideto Nakajima, Tomoyuki Honjo,[...]. Atherosclerosis 2014
52
23

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
Rene A Braeckman, Mehar S Manku, Harold E Bays, William G Stirtan, Paresh N Soni. Prostaglandins Leukot Essent Fatty Acids 2013
37
32

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Christie M Ballantyne, Harold E Bays, Sephy Philip, Ralph T Doyle, Rene A Braeckman, William G Stirtan, Paresh N Soni, Rebecca A Juliano. Atherosclerosis 2016
28
42



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.